Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
13 mai 2021 16h03 HE
|
Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...
Progenity to Report First Quarter 2021 Financial Results and Provide Corporate Update
06 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia
05 mai 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Survey Reveals Pregnant Women Lack Awareness About Preeclampsia, the #2 Cause of Maternal Death
04 mai 2021 07h30 HE
|
Progenity, Inc.
Progenity survey shows more women know their baby’s “fruit size” than the key indicator of a common pregnancy complication Preeclampsia Awareness Month aims to educate women about the potentially...
Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
30 avr. 2021 16h04 HE
|
Progenity, Inc.
SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting
08 avr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
18 mars 2021 16h05 HE
|
Progenity, Inc.
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M...
Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
12 mars 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces $25 Million Private Placement
23 févr. 2021 07h45 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia
12 févr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...